Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MST1R | Q04912 | 8/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | FRK | P42685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802582 | 1.00 | MST1R (0.53) | MST1RSRCKDRMETAXL | |
| SCHEMBL2533156 | 0.92 | MST1R (0.46) | MST1RSRCKDRMETAXL | |
| SCHEMBL2602337 | 0.91 | MST1R (0.46) | MST1RSRCKDRMETAXL | |
| SCHEMBL107493 | 0.89 | MST1R (0.42) | MST1RSRCKDRMETAXL | |
| SCHEMBL14839819 | 0.89 | MST1R (0.42) | MST1RSRCKDRMETAXL | |
| SCHEMBL29935481 | 0.87 | MST1R (0.43) | MST1RSRCKDRMETAXL | |
| SCHEMBL29563599 | 0.86 | MST1R (0.48) | MST1RSRCKDRMETAXL | |
| SCHEMBL172041 | 0.84 | MST1R (0.41) | MST1RSRCSSTR4ROCK2 | |
| SCHEMBL12229310 | 0.84 | MST1R (0.40) | MST1RSRCKDRMETAXL | |
| SCHEMBL2537331 | 0.84 | MST1R (0.55) | MST1RSRCKDRMETAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | WELLMARKER BIO CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | WELLMARKER BIO CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230022859-A1 | TREATMENT OF CANCER WITH ANTI-OX40 ANTIBODIES AND MULTI-KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2023-01-26 | — | — | US | disclosed |
| US-20220402936-A1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. | 2022-12-22 | — | — | US | disclosed |
| US-20220387404-A1 | TREATMENT OF CANCER USING A COMBINATION COMPRISING MULTI-TYROSINE KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BEIGENE, LTD. (KY) | 2022-12-08 | — | — | US | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| US-20210317133-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2021-10-14 | — | — | US | disclosed |
| WO-2021098769-A1 | TREATMENT OF CANCER WITH ANTI-OX40 ANTIBODIES AND MULTI-KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021047623-A1 | TREATMENT OF CANCER USING A COMBINATION COMPRISING MULTI-TYROSINE KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BEIGENE, LTD. (KY) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387404-A1 | TREATMENT OF CANCER USING A COMBINATION COMPRISING MULTI-TYROSINE KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | PDCD1, LCK, CD274 | MST1R 1239/4885SRC 19/4885KDR 1276/4885 |
| US-20230022859-A1 | TREATMENT OF CANCER WITH ANTI-OX40 ANTIBODIES AND MULTI-KINASE INHIBITORS | TNFRSF9, TNFRSF1A, TNFSF11 | MST1R 148/4885SRC 98/4885KDR 579/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | MST1R 759/4885SRC 436/4885KDR 526/4885 |
| US-20210317133-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | MAP4K5, MAP4K2, MAP3K9 | MST1R 1696/4885SRC 392/4885KDR 1939/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MST1R 104/4885SRC 13/4885KDR 11/4885 |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | KRAS, RET, NRAS | MST1R 631/4885SRC 153/4885KDR 502/4885 |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ERBB2, ABL1, FLT1 | MST1R 150/4885SRC 17/4885KDR 5/4885 |
| US-20220402936-A1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | ABL1, LCK, SRC | MST1R 825/4885SRC 3/4885KDR 262/4885 |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | ABL1, ERBB2, TYRO3 | MST1R 136/4885SRC 14/4885KDR 8/4885 |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ABL1, ERBB2, TYRO3 | MST1R 136/4885SRC 14/4885KDR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.